Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
N-[4-(5-fluoro-6-methylpyridin-2-yI)-5-quinoXalin‑6‑yI‑1H‑imidazoI‑2-yI]acetamide is a synthetic small molecule belonging to the quinoxaline class of organic compounds. It has been studied as an experimental inhibitor of the TGF-beta receptor type 1 (TGFBR1), a serine/threonine kinase involved in TGF-beta signaling pathways. Structural studies and biochemical assays indicate that this compound acts as a potent and selective ATP-binding site inhibitor of TGFBR1, with potential applications in modulating fibrotic diseases, cancer, and other conditions where aberrant TGF-beta signaling is implicated[3][7]. The compound has not been approved for clinical use and remains at the experimental stage.
- Other names
- N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-(quinoxalin-6-yl)-1H-imidazol-2-yl]acetamideCHEMBL479262CHEMBL-479262CHEMBL 479262BDBM50255231BDBM-50255231BDBM 50255231BDBM50255179BDBM-50255179BDBM 50255179
02
Targets
TGFBR1
Beyond the preview
Go deeper on N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide.